MedTrace Logo

Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen

NCT02550002 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2022-12-01

No results posted yet for this study

Summary

The primary objective of this study is to test non-inferiority of aflibercept "treat and extend" using a relaxed retinal fluid management relative to aflibercept "treat and extend" using a strict retinal fluid management SD-OCT (spectral domain optical coherence tomography) disease activity guided retreatment with respect to best-corrected visual acuity (BCVA) from baseline to end of treatment.

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

Aflibercept

Intravitreal injection

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Martin Zinkernagel, MD, PhD · Inselspital Bern, Department of Ophthalmology

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2022-03-31
Completion
2022-08-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02550002 on ClinicalTrials.gov